It's currently under consideration as a first-line treatment for advanced or metastatic malignant pleural mesothelioma, among ...

Well-differentiated papillary mesothelioma of the pleura is a rare variant in the spectrum of pleural neoplasmas. This disease has initially been described in the peritoneum of young women without ...

Credit: SewCreamStudio / Shutterstock. Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised neoantigen therapy, in combination with ...

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

Mesothelioma is an aggressive tumor with a poor prognosis. Histological diagnosis of mesothelioma using limited tissue samples can be challenging. Xia & He Publishing Inc.Oct 27 2024 Background and ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

Mesothelioma is an aggressive tumor with a poor prognosis. Histological diagnosis of mesothelioma using limited tissue samples can be challenging. Carbonic anhydrase IX (CAIX) is a transmembrane ...

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

According to Surveillance, Epidemiology and End Result (SEER) data from the National Cancer Institute, the incidence of malignant mesothelioma in 2008 was approximately 1 per 100,000 persons in ...

RAHWAY, N.J. - Merck, known as MSD outside the United States and Canada, has received approval from the European Commission (EC) for two new indications of its anti-PD-1 therapy, KEYTRUDA® ...